Clinician-led telehealth · approved-product first
Explore FDA-approved prescription medicines through an eligibility-first telehealth review—without confusing clinical care with Peakonic’s separate research catalog.
Illustrative clinical-review visuals only—not dispensed packaging. FDA approval belongs to the named manufacturer product, indication, dose, and presentation.
Current FDA data audit · 73 verified medicine groups
Browse verified U.S. product records, open the details, then add a review request. This broad clinical reference includes peptide drugs and closely related peptide/protein medicines; it excludes antibiotics, vaccines, enzymes, and non-U.S. approvals. A licensed clinician—not the storefront—decides whether telehealth, referral, or a prescription is appropriate.
abaloparatide
Parathyroid-hormone-related peptide analog approved for product-specific osteoporosis indications.
afamelanotide
Melanocortin analog approved for a specific phototoxicity indication in erythropoietic protoporphyria.
angiotensin II acetate
Vasopressor peptide approved for tightly supervised treatment of distributive shock.
bivalirudin
Direct thrombin-inhibitor peptide with approved procedural anticoagulation products.
bremelanotide acetate
Approved for a specific sexual-health indication in certain premenopausal women—not general performance or tanning use.
bulevirtide-gmod
Lipopeptide entry inhibitor approved for chronic hepatitis delta virus infection in specified adults.
calcitonin salmon
Calcitonin peptide products have exact, route-specific approved indications and labeling.
cetrorelix acetate
GnRH antagonist approved for controlled ovarian-stimulation protocols.
repository corticotropin
ACTH-family products have narrow, product-specific approved indications and extensive safety labeling.
corticorelin ovine triflutate
Corticotropin-releasing hormone peptide approved for a specialized diagnostic test used in evaluating ACTH-dependent Cushing syndrome.
cosyntropin
Synthetic ACTH fragment approved as a diagnostic agent for adrenal-function testing.
dasiglucagon hydrochloride
Glucagon analog approved for severe hypoglycemia in specified patients.
Availability: FDA approval record verified; current commercial availability must be confirmed.
degarelix acetate
GnRH antagonist approved for advanced prostate cancer.
desmopressin acetate
Vasopressin analog products have route- and indication-specific approvals; formulation substitution is unsafe.
terlipressin acetate
Vasopressin analog approved for adults with hepatorenal syndrome involving rapid reduction in kidney function.
nesiritide
Recombinant B-type natriuretic peptide with an FDA approval record for acute decompensated heart failure.
Availability: FDA approval record verified; listed products are discontinued and current availability must be confirmed.
dulaglutide
Long-acting GLP-1 receptor agonist approved for product-specific diabetes and cardiovascular-risk indications.
elamipretide hydrochloride
Mitochondria-targeting tetrapeptide granted accelerated approval for Barth syndrome in eligible patients.
enfuvirtide
HIV fusion-inhibitor peptide with an FDA approval record for use as part of combination antiretroviral therapy.
Availability: FDA approval record verified; current commercial availability must be confirmed.
ecallantide
Kunitz-domain peptide approved for acute hereditary-angioedema attacks in specified patients.
enlicitide decanoate
Oral cyclic peptide PCSK9 inhibitor approved in July 2026 for specified adults with elevated LDL cholesterol.
eptifibatide
Cyclic heptapeptide antiplatelet medicines approved for acute coronary and procedural settings.
etelcalcetide
Calcimimetic peptide approved for secondary hyperparathyroidism in adults receiving hemodialysis.
exenatide synthetic
GLP-1 receptor agonist products have product-specific diabetes indications and presentations.
ganirelix acetate
GnRH antagonist approved for controlled ovarian-stimulation protocols.
glucagon
Approved glucagon products treat severe hypoglycemia, with route- and device-specific instructions.
goserelin acetate
GnRH agonist implant with product-specific oncology and gynecologic indications.
histrelin acetate
GnRH agonist implant approved for central precocious puberty.
icatibant acetate
Bradykinin B2-receptor antagonist peptide approved for acute hereditary-angioedema attacks in adults.
glatiramer acetate
Synthetic polypeptide mixture approved for relapsing forms of multiple sclerosis.
icotrokinra hydrochloride
Oral cyclic peptide IL-23 receptor antagonist approved in March 2026 for specified psoriasis patients.
human insulin and insulin analogs
Many FDA-approved insulins exist; concentration, device, interchangeability, and indication are product-specific.
insulin icodec
Once-weekly basal insulin analog approved in March 2026 for specified adults with diabetes.
lanreotide acetate
Somatostatin analog products have specific neuroendocrine and acromegaly indications.
leuprolide acetate
Leuprolide products have distinct indications, dosing schedules, and delivery systems.
linaclotide
Guanylate-cyclase-C agonist peptide approved for product-specific chronic constipation disorders.
liraglutide
GLP-1 receptor agonist products have distinct diabetes or chronic weight-management indications.
lixisenatide
GLP-1 receptor agonist products approved for product-specific diabetes use, including a fixed-ratio insulin combination.
lutetium Lu 177 dotatate
Radiolabeled somatostatin analog approved for specified neuroendocrine tumors.
gallium Ga 68 dotatate
Radiolabeled peptide diagnostic approved for PET imaging of somatostatin-receptor-positive neuroendocrine tumors.
copper Cu 64 dotatate
Radiolabeled peptide diagnostic approved for PET localization of somatostatin-receptor-positive neuroendocrine tumors.
gallium Ga 68 edotreotide
Radiolabeled somatostatin analog approved for PET imaging of somatostatin-receptor-positive neuroendocrine tumors.
gallium Ga 68 gozetotide
PSMA-targeted peptide-based radioligand approved for product-specific prostate-cancer PET imaging uses.
indium In 111 pentetreotide
Radiolabeled somatostatin analog with an FDA approval record for scintigraphic localization of neuroendocrine tumors.
Availability: FDA approval record verified; current commercial availability must be confirmed.
lutetium Lu 177 vipivotide tetraxetan
PSMA-targeted peptide-based radioligand approved for specified adults with metastatic prostate cancer.
pegulicianine acetate
Peptide-based fluorescent imaging agent approved as an adjunct for identifying residual cancer during certain breast lumpectomy procedures.
nafarelin acetate
GnRH agonist nasal product with specific approved reproductive-endocrine indications.
navepegritide
Long-acting C-type natriuretic peptide analog approved in February 2026 for eligible children with achondroplasia.
octreotide acetate
Somatostatin analog products have formulation-specific endocrine and neuroendocrine indications.
oxytocin
Approved oxytocin products are used in tightly controlled obstetric settings—not consumer peptide therapy.
palopegteriparatide
Prodrug of parathyroid hormone approved for hypoparathyroidism in adults.
pasireotide
Somatostatin analog products approved for specific pituitary-disorder indications.
pegcetacoplan
C3 inhibitor peptide products have distinct hematology and ophthalmology indications and routes.
motixafortide acetate
Cyclic peptide CXCR4 antagonist approved with filgrastim for stem-cell mobilization before autologous transplant in multiple myeloma.
plecanatide
Guanylate-cyclase-C agonist peptide approved for specified chronic constipation disorders.
pramlintide acetate
Amylin analog with an FDA approval record as adjunctive diabetes therapy.
Availability: FDA approval record verified; current commercial availability must be confirmed.
secretin
Secretin peptide products are approved for specific pancreatic diagnostic testing.
semaglutide
Semaglutide brands have different FDA-approved indications, doses, and presentations; they are not interchangeable by name alone.
setmelanotide acetate
Melanocortin-4 receptor agonist peptide approved for obesity caused by specified rare genetic conditions.
mecasermin recombinant
Recombinant IGF-1 peptide/protein approved for severe primary IGF-1 deficiency in eligible pediatric patients.
somatropin, lonapegsomatropin, somapacitan, and somatrogon
Approved growth-hormone products exist for narrow, product-specific indications; federal law separately restricts distribution for unapproved uses.
teduglutide
GLP-2 analog approved for adults and certain pediatric patients with short bowel syndrome who need parenteral support.
teriparatide
Parathyroid-hormone analog products have exact osteoporosis indications and duration-of-use labeling.
tesamorelin acetate
Tesamorelin has a specific FDA-approved indication; approval does not extend to generic research vials or other uses.
tirzepatide
Tirzepatide brands have distinct FDA-approved indications and exact current labels.
triptorelin pamoate
GnRH agonist depot products have distinct oncology and pediatric endocrine indications.
trofinetide
Synthetic tripeptide analog approved for Rett syndrome in adults and pediatric patients two years of age and older.
vasopressin
Vasopressin peptide products are approved for specific critical-care uses requiring monitored administration.
vosoritide
C-type natriuretic peptide analog approved to increase linear growth in eligible children with achondroplasia.
ziconotide acetate
Conotoxin-derived peptide approved for severe chronic pain through intrathecal infusion.
difelikefalin acetate
D-amino-acid tetrapeptide kappa-opioid receptor agonist approved for moderate-to-severe pruritus in specified adults on hemodialysis.
romidepsin
Cyclic depsipeptide medicine approved for specific T-cell lymphoma indications.
zilucoplan sodium
Cyclic peptide complement inhibitor approved for specified adults with generalized myasthenia gravis.
Approval is product-specific. An approved active ingredient does not make a generic research vial, compounded copy, different salt, route, dose, or use FDA-approved. Prototype estimates are placeholders—not medication prices or quotes. Visit, insurance, manufacturer, and pharmacy costs vary. No prescription is guaranteed.
FDA 503A bulk-substance reference · Category 1
Nominated with enough support for FDA to evaluate and not placed on another list. The current entries shown here include NAD/NAD+, NADH, VIP, and non-injectable GHK-Cu. Informational only on Peakonic. Any compounding requires an eligible compounder and every applicable federal and state condition. This is not approval.
GHK-CuExcept injectable routes of administration
FDA bulk-substance nomination under evaluation; interim enforcement policy may apply to eligible compounders when every condition is met
Not FDA-approved and not a customer-facing treatment listing. This entry does not cover injectable GHK-Cu.
FDA category explanation ↗NAD+Nicotinamide Adenine Dinucleotide (NAD)
Listed by FDA in Category 1 for 503A bulk-substance evaluation as of May 14, 2026
Not FDA-approved. NAD is a dinucleotide coenzyme, not a peptide. Category 1 is an interim compounding-policy status—not an approval, prescription indication, or retail authorization.
FDA category explanation ↗NADHNicotinamide Adenine Dinucleotide Disodium Reduced (NADH)
Listed by FDA in Category 1 for 503A bulk-substance evaluation as of May 14, 2026
Not FDA-approved. This exact reduced disodium substance is a separate Category 1 entry and must not be generalized to every NAD formulation.
FDA category explanation ↗VIPVasoactive Intestinal Peptide (VIP)
Listed by FDA in Category 1 for 503A bulk-substance evaluation as of May 14, 2026
Not FDA-approved. Category 1 status does not establish safety, effectiveness, a labeled use, or a consumer sale pathway.
FDA category explanation ↗FDA 503A bulk-substance reference · Category 2
FDA has identified potential significant safety risks while evaluating the nomination. Outside the Category 1 interim policy. Peakonic marks these entries Not for resale.
MK-677Ibutamoren mesylate
Significant safety concerns identified by FDA
Not for resale. No Category 1 interim enforcement discretion.
FDA category explanation ↗Kisspeptin-10Kisspeptin-10
FDA has identified potential significant safety risks while evaluating the nomination
Not for resale. This is not an FDA-approved medicine and is outside the Category 1 interim policy.
FDA category explanation ↗FDA 503A bulk-substance reference · Category 3
The nomination did not include enough information for FDA to evaluate the substance. Outside the Category 1 interim policy. Peakonic marks these entries Not for resale.
Beta-NADBeta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate
Nomination did not include adequate support for FDA evaluation
Not for resale. This Category 3 entry is chemically and legally distinct from the Category 1 NAD and NADH entries.
FDA category explanation ↗ARA-290Cibinetide (ARA-290)
Nomination did not include adequate support for FDA evaluation
Not for resale. No Category 1 interim enforcement discretion and no FDA-approved product identified.
FDA category explanation ↗GHRP-2Growth hormone-releasing peptide-2
Nomination did not include adequate support for FDA evaluation
Not for resale. No Category 1 interim enforcement discretion.
FDA category explanation ↗GHRP-6Growth hormone-releasing peptide-6
Nomination did not include adequate support for FDA evaluation
Not for resale. No Category 1 interim enforcement discretion.
FDA category explanation ↗L-CarnosineL-Carnosine
Nomination did not include adequate support for FDA evaluation
Not for resale. This exact FDA entry is L-Carnosine; the library’s separate Carnosine record is not treated as equivalent and remains off-list.
FDA category explanation ↗MGFMechano growth factor (MGF)
Nomination did not include adequate support for FDA evaluation
Not for resale. No Category 1 interim enforcement discretion and no FDA-approved product identified.
FDA category explanation ↗Secretin 99%Bulk substance entry: Secretin, human 99%
Nomination did not include adequate support for FDA evaluation
Not for resale. This Category 3 bulk substance is not the same legal product as an FDA-approved, manufacturer-labeled secretin medicine.
FDA category explanation ↗ThymulinAcetate form
Nomination did not include adequate support for FDA evaluation
Not for resale. No Category 1 interim enforcement discretion.
FDA category explanation ↗Separate status · not Category 1, 2, or 3
These learning-library entries have no current Category 1, 2, or 3 listing verified in the stored snapshot. Future agency action is possible, but FDA has not announced approval dates for this group.
BPC-157Status may change only after a verified FDA update.
Advisory review complete; final FDA determination not verified
No FDA-approved human drug. Free-base and acetate forms received July 2026 PCAC review; committee review is not final FDA authorization.
Check current FDA information ↗CJC-1295Status may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved human drug; no current Category 1 pathway verified.
Check current FDA information ↗CardiogenStatus may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; incidental transcript mention and limited foreign/preclinical evidence.
Check current FDA information ↗CarnosineStatus may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
Dietary/supplement and drug questions are product- and claim-specific; inclusion here does not classify every carnosine product as a drug.
Check current FDA information ↗CerebrolysinStatus may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; FDA warning-letter history includes compounded Cerebrolysin products.
Check current FDA information ↗CortexinStatus may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; animal-derived mixture with identity and biologic-source risks.
Check current FDA information ↗CrystagenStatus may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; transcription/identity and evidence require confirmation.
Check current FDA information ↗Emideltide (DSIP)Status may change only after a verified FDA update.
Advisory review complete; final FDA determination not verified
No FDA-approved human drug; free-base and acetate forms received July 2026 PCAC review without a final-list inference.
Check current FDA information ↗EpitalonStatus may change only after a verified FDA update.
Advisory review complete; final FDA determination not verified
No FDA-approved human drug; free-base and acetate forms received July 2026 PCAC review without final-list placement inferred.
Check current FDA information ↗EpithalaminStatus may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; animal-derived extract/mixture.
Check current FDA information ↗IGF-1 LR3Status may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved IGF-1 LR3 human drug; it must not be conflated with FDA-approved mecasermin products.
Check current FDA information ↗IpamorelinStatus may change only after a verified FDA update.
Nomination withdrawn; no current Category 1 pathway
No FDA-approved human drug; FDA safety page states the acetate 503A nomination was withdrawn and identifies safety concerns.
Check current FDA information ↗KPVStatus may change only after a verified FDA update.
Advisory review complete; final FDA determination not verified
No FDA-approved human drug; FDA says it has not identified human exposure data for nominated compounded products.
Check current FDA information ↗LivagenStatus may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; incidental transcript mention and limited foreign/preclinical evidence.
Check current FDA information ↗MOTS-cStatus may change only after a verified FDA update.
Advisory review complete; final FDA determination not verified
No FDA-approved human drug; July 2026 PCAC review is not final authorization.
Check current FDA information ↗Melanotan IIStatus may change only after a verified FDA update.
Nomination withdrawn; no current Category 1 pathway
No FDA-approved human drug; FDA identifies serious case reports and safety/impurity concerns. Distinct from bremelanotide.
Check current FDA information ↗OvagenStatus may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; incidental transcript mention and limited foreign/preclinical evidence.
Check current FDA information ↗Pinealon (EDR)Status may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved human drug; evidence discussed is largely preclinical, foreign, or anecdotal.
Check current FDA information ↗RetatrutideStatus may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
Investigational; no FDA-approved retatrutide product as of the database date.
Check current FDA information ↗SemaxStatus may change only after a verified FDA update.
Advisory review complete; final FDA determination not verified
No FDA-approved human drug; FDA lists safety-information gaps and July 2026 PCAC review is not final authorization.
Check current FDA information ↗TB-500Status may change only after a verified FDA update.
Advisory review complete; final FDA determination not verified
No FDA-approved human drug; it is a fragment related to, but not the same as, full thymosin beta-4.
Check current FDA information ↗ThymalinStatus may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; animal-derived mixtures add identity, contamination, and prion-risk questions.
Check current FDA information ↗ThymogenStatus may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; limited foreign/preclinical evidence.
Check current FDA information ↗Thymosin alpha-1Status may change only after a verified FDA update.
Nomination withdrawn; no current Category 1 pathway
No current FDA-approved U.S. human drug identified; speaker's FDA-approval statement conflicts with current U.S. screening. FDA lists a withdrawn nomination and safety-information gaps.
Check current FDA information ↗Thymosin beta-4Status may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
Distinct from TB-500. No FDA-approved human thymosin beta-4 drug identified for this screening database.
Check current FDA information ↗Thymosin fraction 5Status may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved human drug identified in this screening.
Check current FDA information ↗VilonStatus may change only after a verified FDA update.
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; limited foreign/preclinical evidence.
Check current FDA information ↗Scope note: This is the intersection with Peakonic’s 42-compound learning library—not every substance in FDA’s full category documents.
Step 1 of 4
Start with where you will be during the visit and what you want help with. Do not enter health details in this prototype.
Eligibility screen
A licensed clinician must determine whether telehealth and any prescription are appropriate.
The Peakonic model
The care experience is designed around authorization, appropriate evaluation, transparent routing, and continuity—not a medication-first checkout.
Current state, age, visit goal, and emergency boundary.
History, medications, allergies, records, and labs when needed.
An authorized clinician determines whether telehealth and treatment are appropriate.
The outcome may be an FDA-approved medicine, another plan, referral, or no prescription.
If prescribed, the clinician sends the prescription to an eligible licensed pharmacy, with transparent costs and follow-up.
Primary-source standard
Medication approvals, compounding rules, and state telehealth requirements can change. Peakonic keeps the clinical route tied to current primary sources and separates it from the 42-compound research library.
Separate storefront
Research-use products have different labels, a different cart, and no clinical pathway. They never appear in the care cart.